GEN Editors Reflect on Six of the Biggest Stories of the Year

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

genengnews.com

NeurIPS 2025: Altos Labs Wins Generalist Prize at Arc's Virtual Cell Challenge

The inaugural competition surprisingly awarded two $100,000 grand prizes to address challenges in defining robust benchmarks for complex biology.

genengnews.com

AI in Protein Design: Hype vs. Reality Explained by David Baker

In this GEN interview, Nobel Laureate David Baker, PhD, emphasizes that designing proteins from scratch is reality and unpacks what's needed for AI to transform medicine.

genengnews.com

The State of AI in Drug Discovery 2025, Wed, Oct 29th, 2025 @ 11:00 AM Mary Ann Liebert, Inc. publishers

Artificial intelligence (AI) and machine learning partnered with big data generation at unprecedented scale is transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. From generative AI to unlock novel drug candidates to virtual cells that gleam insights across multimodal biology, we are witnessing the cusp of an exponential curve of AI innovation that is poised to enhance and perhaps overhaul the design and validation of novel therapeutics. In 2024, GEN debuted our virtual summit, The State of AI in Drug Discovery, which drew a record audience. This year’s summit provides a platform for an outstanding group of researchers, evangelists and entrepreneurs to showcase the latest advances, applications and challenges regarding the deployment of AI across therapeutic development. The program features many of the most exciting companies and organizations powering the AI revolution, including NVIDIA, Xaira Therapeutics, Recursion, Chan Zuckerberg Initiative, Arc Institute, Generate: Biomedicines, and more! Please join us on October 29th for a dynamic program featuring: A featured presentation with Bo Wang, PhD (Xaira Therapeutics) on the promise of multimodal AI for health care The democratization of small molecule drug discovery with the developers of Boltz-2, Gabriele Corso, PhD (MIT), Regina Barzilay, PhD (MIT), and Najat Khan, PhD (Recursion) Evolving industry trends across the AI therapeutic landscape with Derek Lowe, PhD (Novartis and author of "In the Pipeline"), Molly Gibson, PhD, (Flagship Pioneering), and Stacie Calad-Thomson, PhD (NVIDIA) Building the virtual cell with Theofanis Karaletsos (Chan Zuckerberg Initiative), Emma Lundberg, PhD (Stanford), Hani Goodarzi, PhD (Arc Institute), and Ron Alfa, MD, PhD (Noetik) What’s next for AI in protein design with Surge Biswas, PhD (Nabla Bio), Tharindi Hapuarachchi, PhD (Generate: Biomedicines), and Oliver Vince, PhD (Basecamp Research) Breakout sessions from our event sponsors, Revvity Signals, Benchling, and Telesis Bio. Registration for The State of AI in Drug Discovery is entirely free. Sponsored by

webinars.liebertpub.com

AI-Designed Protein Switches Control Drugs with Speed

David Baker’s Nobel Prize-winning lab has designed protein on/off switches as a tool for tunable cancer immunotherapies and biosensors.

genengnews.com

AI Designs Viable Bacteriophage Genomes, Combats Antibiotic Resistance

AI-guided design of 16 functional bacteriophage genomes offers a path for phage-based therapies against antibiotic-resistant infections.

genengnews.com

BindCraft AI Model Achieves One-Shot Functional Protein Design

The open-source pipeline designs proteins with improved success rates for therapeutic targets, including gene editing proteins and allergens.

genengnews.com

Profluent’s AI-Designed Gene Editor Provides Glimpse Into Generalizable Platform

OpenCRISPR-1, an AI-generated custom gene editor capable of precision editing of the human genome. is just the beginning of Profluent’s AI applications.

genengnews.com

Jura Bio’s AI Data Loop Enables Large-Scale De Novo Antibody Design

VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.

genengnews.com

Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets

David Baker’s lab has successfully designed binders to disordered proteins, expanding therapeutic access to over 50% of the human proteome.

tinyurl.com

Democratizing Artificial Intelligence in Pre-Clinical Drug Discovery

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

genengnews.com

Arc Institute Launches Virtual Cell Challenge to Accelerate AI Model Development

The open benchmark competition will evaluate the ability of AI-powered virtual cell models to generalize to new cell contexts for therapeutic applications.

genengnews.com

Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

genengnews.com

Million Species Listing: Basecamp Research Unearths Trove of Sequence Data From Novel Species

BaseData aims to improve AI models in biology by offering a 10-fold expansion of protein diversity compared to all public databases combined.

genengnews.com

Boltz-2 Released to Democratize AI Molecular Modeling for Drug Discovery

The MIT model predicts molecular binding affinity at newfound speed and accuracy, offering a powerful tool for commercial drug discovery.

genengnews.com

Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox

Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the clinic faster.

tinyurl.com

Imprint Labs Launches to Pioneer "Forensic Immunology" For Chronic Disease

Imprint has raised $15 million to decode the body's immune memory for understanding chronic diseases, such as long-COVID and psychiatric disorders.

genengnews.com

ASGCT 2025: World’s First Patient Treated with Personalized CRISPR Therapy

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows improvement from a rare metabolic disease.

genengnews.com

The Cross-Species Cell Atlas: Chan Zuckerberg Initiative Releases TranscriptFormer AI Model

Trained on data covering 1.5 billion years of evolution, CZI’s new generative AI model probes cellular biology across species for therapeutic applications.

genengnews.com

Machine Learning Engineers Bespoke Cas9 Enzymes for Gene Editing

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

genengnews.com

Arc Institute’s AI Model Evo 2 Designs the Genetic Code Across All Domains of Life

Evo 2 now includes information from humans, plants, and other eukaryotic species to expand its capabilities in generative functional genomics.

tinyurl.com

AI-Guided Receptor Engineering to Improve Performance in Cell Therapies

Using protein structure prediction tools, researchers have uncovered receptor structure-function relationships to improve cell therapies.

genengnews.com

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

genengnews.com

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

tinyurl.com